Ikarian Capital, LLC Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $17.1 Million - $29.5 Million	-119,300 Reduced 98.76%	1,500 $364,000
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $7.16 Million - $9.69 Million	-48,900 Reduced 28.82%	120,800 $18.1 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $25.7 Million - $33.4 Million	169,700 New	169,700 $32.5 Million
Q2 2022 Aug 12, 2022	BUY	$120.42 - $169.29 $18.8 Million - $26.4 Million	156,100 Added 115.46%	291,300 $42.5 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $5.48 Million - $7.5 Million	-43,100 Reduced 24.17%	135,200 $22.1 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $239,340 - $313,935	-1,500 Reduced 0.83%	178,300 $30.2 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $2.7 Million - $3.3 Million	-15,900 Reduced 8.12%	179,800 $33.9 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $25.2 Million - $34.6 Million	195,700 New	195,700 $33.2 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $25.7 Million - $38.6 Million	-246,900 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $23 Million - $33.1 Million	246,900 New	246,900 $26.9 Million

643

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.